This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Edward B. Nelson, MD, PhD; Bernadette P. McKeon, PharmD
Merck & Co Inc West Point, Pa

JAMA. 1993;270(24):2924.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—The Treatment of Mild Hypertension Study (TOMHS)¹ represents a worthy contribution to the evaluation of therapeutic interventions on outcomes in patients with mild hypertension. The use of broad categories of morbidity and mortality outcomes demonstrated the overall benefit of antihypertensive agents plus lifestyle modification compared with lifestyle modification alone. Blood pressure reductions with all five antihypertensive agents (acebutolol, amlodipine maleate, chlorthalidone, doxazosin mesylate, and enalapril maleate) plus lifestyle modification were significantly greater than with lifestyle modification alone for "all follow-up BP [blood pressure] measurements."

The significance of blood pressure reduction was also addressed in the accompanying Editorial² stating, "All classes of drugs, with the exception of the angiotensin-converting enzyme inhibitor (enalapril), were equally effective in lowering blood pressure in TOMHS and all were superior to the lifestyle-modification regimen given with placebo." Clarification of this statement is needed because the drug dosages evaluated in TOMHS were . . . [Full Text PDF of this Article]

Footnotes
Edited by Drummond Rennie, MD, Deputy Editor (West), and Margaret A. Winker, MD, Senior Editor.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?